Clinical Trial Update: An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE [Phase 2, Phase 3]

View source ↗

Summary

Open-label extension study assessing inhaled treprostinil in adults with pulmonary hypertension associated with interstitial lung disease, including CPFE; trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Pulmonary Fibrosis and Emphysema
• Interstitial Lung Disease
• Pulmonary Hypertension

Drugs mentioned

• Treprostinil (inhaled) (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Hypertension, Interstitial Lung Disease | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2022-12-02